A Phase 2 interventional study of Ranibizumab 0.5 mg and Panretinal laser photocoagulation in Proliferative Diabetic Retinopathy (PDR), sponsored by Novartis Pharmaceuticals. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 9 in phase 2, and was the 16th registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Affiliated Hospital of Nantong University · Sites in China
Ages 18–80
Southeast Retina Center, Georgia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 9 · Phase 4 10
First in 2006; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 57 across the 34 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
15 studies in Diabetic Retinopathy by Novartis: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 15 studies in Diabetic Retinopathy by Novartis, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2, and was the 8th registered.
Novartis’s Diabetic Retinopathy studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, from their registry updates:
Among Novartis’s 15 in Diabetic Retinopathy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in patients with Proliferative Diabetic Retinopathy (PDR).
A 12-month core phase was followed by a 12-month observational follow-up phase (physician's routine), for a planned individual study duration of 24-25 months. A separate informed consent was signed for the 12-month observational follow-up phase. This study was conducted in Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
Drug: Ranibizumab 0.5 mg
Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
Procedure: Panretinal laser photocoagulation
Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
Drug: Ranibizumab 0.5 mg · Procedure: Panretinal laser photocoagulation
Pre-filled syringe for intravitreal injection
Also known as: Lucentis®, RFB002
PRP treatment following DRS guidelines
Also known as: PRP
Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS)
The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.
Time frame: Baseline, EOCS
Change From Baseline in Area of Neovascularizations (NVs) at Month 3
The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Month 3
Best Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. A higher number of ETDRS letters may indicate better visual acuity. One eye (study eye) contributed to the analysis.
Time frame: EOCS
Percentage of Patients With Change From Baseline in BCVA (ETDRS Letters) at EOCS
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. No clinically relevant change was defined as \<5 letters gain or loss. A higher positive change value may indicate a greater improvement in visual acuity. One eye (study eye) contributed to the analysis.
Time frame: Baseline, EOCS
Number of Patients With Change From Baseline in ETDRS Severity Grade of Diabetic Retinopathy (DR) at EOCS
The severity level of diabetic retinopathy was determined using the ETDRS severity scale. However, in contrast to the original ETDRS severity scale, wide field fluorescein angiography images were used in addition to color fundus photography for identification of NVs and prior PRP treatment was not considered for determining the severity level. Eyes could be graded in the following classes: "DR absent" (10), "questionable DR" (14,15), "NPDR" (20-53), "mild PDR" (60-61), "moderate PDR" (65), "high risk PDR" (71-75), "advanced PDR" (81-85) and "cannot grade" (90). One eye (study eye) contributed to the analysis. No statistical analysis was conducted for ≥ 1 class deterioration or ≥ 2 class deterioration from Baseline at EOCS because ratios could not be calculated in case of zero frequencies in at least one of the three treatment groups.
Time frame: Baseline, EOCS
Change From Baseline in Central Subfield Thickness at EOCS
Central subfield retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.
Time frame: Baseline, EOCS
Change From Baseline in Foveal Center Point Retinal Thickness at EOCS
Foveal center point retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.
Time frame: Baseline, EOCS
Number of Ranibizumab Injections Until EOCS
The total number of ranibizumab injections until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.
Time frame: Baseline to EOCS
Number of PRP Laser Spots Until EOCS
The total number of PRP laser spots from baseline until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.
Time frame: Baseline to EOCS
Patients were screened for eligibility at 23 German study sites and randomized at 22 of the 23 sites.
| Milestone | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Started | 36 | 36 | 36 |
| Full analysis set (fas) | 35 | 35 | 36 |
| Completed | 29 | 26 | 28 |
| Not completed | 7 | 10 | 8 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Subject withdrew consent | 0 | 1 | 1 |
| Withdrew: Death | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 4 | 1 |
| Withdrew: Adverse event | 4 | 4 | 4 |
| Milestone | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Started | 28 | 21 | 25 |
| Follow up set (fus) | 28 | 20 | 25 |
| Completed | 25 | 19 | 23 |
| Not completed | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 |
| Withdrew: Administrative problems | 0 | 0 | 1 |
| Withdrew: Subject withdrew consent | 1 | 0 | 1 |
The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.
| square millimeters | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS) | -4.6 ± 11.3 | -0.9 ± 3.9 | -1.7 ± 3.0 |
The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.
| square millimeters | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Change From Baseline in Area of Neovascularizations (NVs) at Month 3 | -5.9 ± 12.7 | -0.7 ± 2.8 | -2.7 ± 3.9 |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. A higher number of ETDRS letters may indicate better visual acuity. One eye (study eye) contributed to the analysis.
| letters | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Best Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS | 84.4 ± 8.6 | 76.8 ± 17.0 | 78.9 ± 12.2 |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. No clinically relevant change was defined as \<5 letters gain or loss. A higher positive change value may indicate a greater improvement in visual acuity. One eye (study eye) contributed to the analysis.
| percentage of participants | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| ≥15 letters gain from Baseline at EOCS | 0.0 | 2.9 | 0.0 |
| ≥10 letters gain from Baseline at EOCS | 5.7 | 11.4 | 8.3 |
| ≥5 letters gain from Baseline at EOCS | 31.4 | 20.0 | 13.9 |
| No clinically relevant change from Baseline | 51.4 | 42.9 | 61.1 |
| ≥5 letters loss from Baseline at EOCS | 17.1 | 37.1 | 25.0 |
| ≥10 letters loss from Baseline at EOCS | 11.4 | 11.4 | 8.3 |
| ≥15 letters loss from Baseline at EOCS | 2.9 | 8.6 | 2.8 |
The severity level of diabetic retinopathy was determined using the ETDRS severity scale. However, in contrast to the original ETDRS severity scale, wide field fluorescein angiography images were used in addition to color fundus photography for identification of NVs and prior PRP treatment was not considered for determining the severity level. Eyes could be graded in the following classes: "DR absent" (10), "questionable DR" (14,15), "NPDR" (20-53), "mild PDR" (60-61), "moderate PDR" (65), "high risk PDR" (71-75), "advanced PDR" (81-85) and "cannot grade" (90). One eye (study eye) contributed to the analysis. No statistical analysis was conducted for ≥ 1 class deterioration or ≥ 2 class deterioration from Baseline at EOCS because ratios could not be calculated in case of zero frequencies in at least one of the three treatment groups.
| participants | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| ≥ 1 class improvement from Baseline at EOCS | 10 | 9 | 13 |
| ≥ 2 class improvement from Baseline at EOCS | 2 | 2 | 5 |
| ≥ 1 class deterioration from Baseline at EOCS | 2 | 0 | 1 |
| ≥ 2 class deterioration from Baseline at EOCS | 0 | 0 | 0 |
Central subfield retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.
| micrometer | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Change From Baseline in Central Subfield Thickness at EOCS | -6.0 ± 15.1 | 36.2 ± 55.9 | 17.6 ± 46.7 |
Foveal center point retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.
| micrometer | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Change From Baseline in Foveal Center Point Retinal Thickness at EOCS | -4.7 ± 21.2 | 48.1 ± 83.7 | 25.5 ± 53.5 |
The total number of ranibizumab injections until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.
| injections | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Number of Ranibizumab Injections Until EOCS | 5.2 ± 2.3 | NA ± NA | 5.0 ± 2.2 |
The total number of PRP laser spots from baseline until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.
| PRP laser spots | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP |
|---|---|---|---|
| Number of PRP Laser Spots Until EOCS | NA ± NA | 1919.4 ± 673.1 | 1670.0 ± 568.4 |
Collected over Adverse Events (AEs) were collected from time of informed consent until 4 weeks after the patient has stopped study participation (approximately 2 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab Mono Until Month 12 | 1/35 (2.9%) | 8/35 (22.9%) | 34/35 (97.1%) |
| PRP Mono Until Month 12 | 1/35 (2.9%) | 11/35 (31.4%) | 29/35 (82.9%) |
| Ranibizumab+PRP Until Month 12 | 2/36 (5.6%) | 16/36 (44.4%) | 34/36 (94.4%) |
| Ranibizumab Mono Month 12 to 24 | 0/28 (0%) | 5/28 (17.9%) | 21/28 (75%) |
| PRP Mono Month 12 to 24 | 0/20 (0%) | 5/20 (25%) | 12/20 (60%) |
| Ranibizumab+PRP Month 12 to 24 | 0/25 (0%) | 11/25 (44%) | 21/25 (84%) |
| Event | Ranibizumab Mono Until Month 12 | PRP Mono Until Month 12 | Ranibizumab+PRP Until Month 12 | Ranibizumab Mono Month 12 to 24 | PRP Mono Month 12 to 24 | Ranibizumab+PRP Month 12 to 24 |
|---|---|---|---|---|---|---|
| DIABETIC RETINOPATHY (Left eye)Eye disorders | 1/35 | 1/35 | 0/36 | 0/28 | 2/20 | 2/25 |
| DIABETIC FOOT (Non-ocular)Skin and subcutaneous tissue disorders | 0/35 | 1/35 | 3/36 | 0/28 | 0/20 | 0/25 |
| VITREOUS HAEMORRHAGE (Right eye)Eye disorders | 1/35 | 2/35 | 0/36 | 0/28 | 0/20 | 2/25 |
| DIABETIC RETINOPATHY (Right eye)Eye disorders | 0/35 | 1/35 | 2/36 | 0/28 | 1/20 | 1/25 |
| CEREBROVASCULAR ACCIDENT (Non-ocular)Nervous system disorders | 1/35 | 0/35 | 2/36 | 0/28 | 0/20 | 0/25 |
| HEART VALVE STENOSIS (Non-ocular)Cardiac disorders | 0/35 | 0/35 | 0/36 | 0/28 | 1/20 | 0/25 |
| TENDON RUPTURE (Non-ocular)Injury, poisoning and procedural complications | 0/35 | 0/35 | 0/36 | 0/28 | 1/20 | 0/25 |
| BLOOD GLUCOSE FLUCTUATION (Non-ocular)Investigations | 0/35 | 0/35 | 1/36 | 0/28 | 1/20 | 0/25 |
| PSYCHIATRIC DECOMPENSATION (Non-ocular)Psychiatric disorders | 0/35 | 0/35 | 0/36 | 0/28 | 1/20 | 0/25 |
| CONGESTIVE CARDIOMYOPATHY (Non-ocular)Cardiac disorders | 0/35 | 0/35 | 0/36 | 0/28 | 0/20 | 1/25 |
| Event | Ranibizumab Mono Until Month 12 | PRP Mono Until Month 12 | Ranibizumab+PRP Until Month 12 | Ranibizumab Mono Month 12 to 24 | PRP Mono Month 12 to 24 | Ranibizumab+PRP Month 12 to 24 |
|---|---|---|---|---|---|---|
| RETINAL NEOVASCULARISATION (Right eye)Eye disorders | 12/35 | 3/35 | 10/36 | 5/28 | 2/20 | 4/25 |
| NASOPHARYNGITIS (Non-ocular)Infections and infestations | 7/35 | 12/35 | 9/36 | 2/28 | 2/20 | 3/25 |
| VISUAL ACUITY REDUCED (Left eye)Eye disorders | 5/35 | 3/35 | 12/36 | 2/28 | 1/20 | 1/25 |
| RETINAL NEOVASCULARISATION (Left eye)Eye disorders | 5/35 | 4/35 | 9/36 | 8/28 | 0/20 | 4/25 |
| VITREOUS HAEMORRHAGE (Right eye)Eye disorders | 4/35 | 7/35 | 5/36 | 3/28 | 1/20 | 7/25 |
| VISUAL ACUITY REDUCED (Right eye)Eye disorders | 7/35 | 9/35 | 5/36 | 3/28 | 3/20 | 1/25 |
| MACULAR OEDEMA (Right eye)Eye disorders | 3/35 | 8/35 | 4/36 | 5/28 | 1/20 | 4/25 |
| DIABETIC RETINOPATHY (Left eye)Eye disorders | 7/35 | 1/35 | 7/36 | 2/28 | 0/20 | 4/25 |
| MACULAR OEDEMA (Left eye)Eye disorders | 5/35 | 4/35 | 4/36 | 2/28 | 4/20 | 3/25 |
| RETINAL NEOVASCULARISATION (Both eyes)Eye disorders | 1/35 | 1/35 | 2/36 | 0/28 | 0/20 | 5/25 |
Safety Set
| Age, Continuous(Years) | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP | Total |
|---|---|---|---|---|
| Mean | 52.5 ± 11.0 | 53.0 ± 12.1 | 55.0 ± 13.4 | 53.5 ± 12.1 |
| Sex: Female, Male(Participants) | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP | Total |
|---|---|---|---|---|
| Female | 14 | 11 | 8 | 33 |
| Male | 21 | 24 | 28 | 73 |
| Race and Ethnicity Not Collected(Participants) | Ranibizumab Mono | PRP Mono | Ranibizumab+PRP | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
No publications or documents are linked to this record.
Ran from Dec 2012 to primary completion in Nov 2016, 47 months.
Results were first posted in Mar 2019, 2 years 3 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 47 months is above that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab